Findings

What do systematic reviews say?

24 questions · 24 findings · 1 reviews · ENT

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 4.2%GRADE not reported 0 · 0%Very low 8 · 33.3%Low 8 · 33.3%Moderate 5 · 20.8%High 2 · 8.3%

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Extent of disease ‐ CT scan (lower score = better) · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
High

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 766 participants
Moderate

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps

Anti‐IL‐4Rα mAb (dupilumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat (longest… compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 0.95 [0.72, 1.25]
3 studies · 783 participants
Low

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low